Trypanothione reductase is thought to be important in maintaining an intracellular reducing environment in trypanosomatids. To investigate the role of trypanothione reductase we transfected Leishmania donovani and Trypanosoma cruzi with an expression vector containing the L. donovani trypanothione reductase gene and achieved over-expression of enzyme activity (10-14-fold) in transformed cells. Following treatment of L. donovani cells with the thiol-oxidizing agent diamide, the ability to regenerate dihydrotrypanothione from trypanothione disulphide was considerably enhanced in cells which over-expressed trypanothione reductase. However, the growth of transformed and control cells was equally sensitive to inhibition by nifurtimox, nitrofurazone and gentian violet, drugs that are thought to act by inducing oxidative damage. Likewise, growth of transformed and control cells were equally susceptible to inhibition by hydrogen peroxide, and control and transformed L. donovani promastigotes metabolized hydrogen peroxide at comparable rates. Thus, these experiments suggest that the ability to regenerate dihydrotrypanothione from trypanothione disulphide is not a rate-limiting step in the metabolism of hydrogen peroxide.Trypanosomatids are flagellated parasitic protozoa which include the causative agents of Chagas' disease (Trypanosoma cruzi) and visceral and cutaneous leishmaniasis (Leishmania spp.). Chagas' disease affects up to 20 million people in Latin America [l] and world-wide there are estimated to be 400000 new cases of leishmaniasis/year [2]. There are no reliable vaccines against trypanosomatid infections and in many cases, particularly with Chagas' disease, treatment with drugs currently available is unsatisfactory due to toxicity or limited efficacy [3]. The development of more effective chemotherapy for these diseases is thus a major research priority. Approaches to drug design are now aimed at the identification of essential biochemical processes which are pathogen-specific as targets for chemotherapy. One unique feature of trypanosomatid metabolism which would appear to fulfil these criteria is the trypanothione system [4] and in particular the enzyme trypanothione reductase, an NADPHdependent FAD-containing oxidoreductase [4, 51. Indeed the trypanothione system has been implicated as a possible target for several drugs currently used in the treatment of trypanosomatid infections (reviewed in [61).Trypanothione is maintained in its reduced form [T(SH),] by trypanothione reductase. The trypanothione reductase gene has now been cloned from Trypanosoma congolense